{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:35:53Z","timestamp":1793738153888,"version":"4.6.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270648"],"award-info":[{"award-number":["82270648"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203785"],"award-info":[{"award-number":["82203785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473470"],"award-info":[{"award-number":["82473470"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2024HXBH073"],"award-info":[{"award-number":["2024HXBH073"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018525","name":"Key Research and Development Program of Sichuan Province","doi-asserted-by":"publisher","award":["2024YFFK0309"],"award-info":[{"award-number":["2024YFFK0309"]}],"id":[{"id":"10.13039\/501100018525","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018525","name":"Key Research and Development Program of Sichuan Province","doi-asserted-by":"publisher","award":["2024YFFK0310"],"award-info":[{"award-number":["2024YFFK0310"]}],"id":[{"id":"10.13039\/501100018525","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104981","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:34:11Z","timestamp":1760938451000},"page":"104981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clinical efficacy and challenges of cancer-testis antigen vaccines in advanced solid tumors: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"216","author":[{"given":"Jinting","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangneng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jier","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3424-0446","authenticated-orcid":false,"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2025.104981_bib1","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24882","article-title":"Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens","volume":"2","author":"Aruga","year":"2013","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104981_bib2","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/1078-0432.CCR-12-3592","article-title":"Long-term vaccination with multiple peptides derived from Cancer-Testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer","volume":"19","author":"Aruga","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104981_bib3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104981_bib4","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR t cells and T-Cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"Jama"},{"key":"10.1016\/j.critrevonc.2025.104981_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122559","article-title":"Emerging adjuvants for intradermal vaccination","volume":"632","author":"Chen","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104981_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2326-6066.CIR-18-0198","article-title":"Autologous lymphocyte infusion supports tumor antigen Vaccine-Induced immunity in autologous stem cell transplant for multiple myeloma","volume":"7","author":"Cohen","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.104981_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1034\/j.1600-065X.2002.18804.x","article-title":"Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen","volume":"188","author":"Coulie","year":"2002","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2025.104981_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: current perspectives","volume":"9","author":"Debela","year":"2021","journal-title":"SAGE Open Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104981_bib9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2217\/imt.15.29","article-title":"MAGE-A3: an immunogenic target used in clinical practice","volume":"7","author":"Esfandiary","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2025.104981_bib10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.semcancer.2021.04.016","article-title":"Cancer\/testis antigens: from serology to mRNA cancer vaccine","volume":"76","author":"Fan","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104981_bib12","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood-2008-07-168666","article-title":"Peripheral blood lymphocytes genetically modified to express the self\/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients","volume":"113","author":"Fontana","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104981_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4161\/cbt.12.3.15949","article-title":"Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker and potential targets for immunotherapy","volume":"12","author":"Forghanifard","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"3_","key":"10.1016\/j.critrevonc.2025.104981_bib14","first-page":"895s","article-title":"Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12","volume":"7","author":"Gajewski","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104981_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.0105-2896.2004.00139.x","article-title":"Cancer immunotherapy with mRNA-transfected dendritic cells","volume":"199","author":"Gilboa","year":"2004","journal-title":"Immunol. Rev."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104981_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12070717","article-title":"Development and clinical applications of therapeutic cancer vaccines with individualized and shared neoantigens","volume":"12","author":"Hao","year":"2024","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104981_bib18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104981_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00262-003-0429-0","article-title":"Phase I\/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma","volume":"53","author":"Hersey","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104981_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1479-5876-12-84","article-title":"Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients","volume":"12","author":"Iinuma","year":"2014","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104981_bib21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00262-020-02483-1","article-title":"First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors","volume":"69","author":"Ishihara","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104981_bib22","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1007\/s00262-021-02892-w","article-title":"Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients","volume":"70","author":"Ishikawa","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104981_bib23","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1111\/j.1349-7006.2010.01732.x","article-title":"Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ t cell response in patients with metastatic esophageal squamous cell carcinoma","volume":"101","author":"Iwahashi","year":"2010","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104981_bib24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ijc.24850","article-title":"Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and montanide ISA-51: association with survival","volume":"126","author":"Karbach","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104981_bib25","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/j.1349-7006.2012.02370.x","article-title":"SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese musculoskeletal oncology group","volume":"103","author":"Kawaguchi","year":"2012","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-3-1","article-title":"Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma","volume":"3","author":"Kawaguchi","year":"2005","journal-title":"J. Transl. Med."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104981_bib27","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the european organisation for research and treatment of cancer melanoma group in metastatic melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104981_bib28","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3389\/fimmu.2018.02454","article-title":"A task force against local inflammation and cancer: lymphocyte trafficking to and within the skin","volume":"9","author":"Lafouresse","year":"2018","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43556-024-00241-8","article-title":"Cancer vaccines: platforms and current progress","volume":"6","author":"Lei","year":"2025","journal-title":"Mol. Biomed."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104981_bib31","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1158\/1078-0432.CCR-08-2484","article-title":"Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma","volume":"15","author":"Nicholaou","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104981_bib32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/jjco\/hys069","article-title":"Cancer peptide vaccine therapy developed from oncoantigens identified through Genome-wide expression profile analysis for bladder cancer","volume":"42","author":"Obara","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104981_bib33","first-page":"6076","article-title":"NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer","volume":"63","author":"Odunsi","year":"2003","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104981_bib34","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1117208109","article-title":"Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients","volume":"109","author":"Odunsi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104981_bib36","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104981_bib37","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104981_bib38","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5519","article-title":"Cancer testis antigen subfamilies: attractive targets for therapeutic vaccine (Review)","volume":"62","author":"Ren","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104981_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res."},{"issue":"7823","key":"10.1016\/j.critrevonc.2025.104981_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104981_bib42","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104981_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-Engineered t cells: current strategies, challenges, and prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front Immunol."},{"issue":"30","key":"10.1016\/j.critrevonc.2025.104981_bib44","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1200\/JCO.2008.17.3161","article-title":"Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens","volume":"26","author":"Slingluff","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1847846","article-title":"A phase 1b study evaluating the safety, tolerability, and immunogenicity of CMB305, a Lentiviral-Based Prime-Boost vaccine regimen, in patients with locally advanced, relapsed, or metastatic cancer expressing NY-ESO-1","volume":"9","author":"Somaiah","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2025.104981_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","article-title":"Decisions about dendritic cells: past, present, and future","volume":"30","author":"Steinman","year":"2012","journal-title":"Annu Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104981_bib47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1479-5876-11-97","article-title":"Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer","volume":"11","author":"Suzuki","year":"2013","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib48","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1186\/s12964-024-01854-w","article-title":"Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance","volume":"22","author":"Tang","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.critrevonc.2025.104981_bib49","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol."},{"issue":"35","key":"10.1016\/j.critrevonc.2025.104981_bib50","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2005.08.375","article-title":"Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by t cells","volume":"23","author":"van Baren","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104981_bib51","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104981_bib52","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104981_bib53","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/ijc.23810","article-title":"Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination","volume":"123","author":"Wada","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"34","key":"10.1016\/j.critrevonc.2025.104981_bib54","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib55","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s40425-019-0787-6","article-title":"Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer","volume":"7","author":"Westdorp","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104981_bib56","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","article-title":"A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients","volume":"24","author":"Wilgenhof","year":"2013","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104981_bib57","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/CJI.0b013e31821dcb31","article-title":"Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma","volume":"34","author":"Wilgenhof","year":"2011","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104981_bib59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104981_bib60","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/1078-0432.CCR-14-0202","article-title":"Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS","volume":"21","author":"Yoshitake","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104981_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1022307","article-title":"A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS","volume":"4","author":"Yoshitake","year":"2015","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104981_bib62","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00262-014-1640-x","article-title":"A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent\/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)","volume":"64","author":"Zandberg","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104981_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.286","article-title":"Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: a meta-analysis","volume":"4","author":"Zhang","year":"2023","journal-title":"MedComm"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:07:11Z","timestamp":1773302831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":63,"alternative-id":["S1040842825003695"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104981","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and challenges of cancer-testis antigen vaccines in advanced solid tumors: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104981"}}